September 9, 2021 News by Steve Bryson, PhD ADS-5102 Aided Walking Speed in Select MS Patients in INROADS Trial An extended-release formulation of amantadine, ADS-5102 was significantly more effective than a placebo at increasing walking speed in multiple sclerosis (MS) patients who had difficulty with this, particularly younger patients with a shorter disease course, the INROADS Phase 3 trial demonstrated. Further clinical work on this investigative…
August 6, 2021 News by Steve Bryson, PhD MD1003 Aids Walking Speed in Progressive MS, But Carries Risks High-dose biotin aided walking speed in people with progressive multiple sclerosis after 12 to 15 months as an add-on treatment, an analysis of placebo-controlled clinical trials shows. However, the therapy failed to improve other measures of disability, and was associated with inaccurate lab test results caused by high levels…
October 29, 2020 News by Marta Figueiredo, PhD MD1003 Fails to Prevent Disability Progression in Progressive MS Patients, Trial Shows MD1003, MedDay Pharmaceuticalsā high-dose biotin therapy, failed to significantly improve functional ability or walking speed in people with non-active progressiveĀ multiple sclerosis (MS), according to data from a Phase 3 clinical trial. Besides failing to meet the trialās goals, the therapy was associated with inaccurate results in…
June 29, 2020 Columns by Ed Tobias MS News That Caught My Eye Last Week: Mayzent, Hookworm Therapy, Walking and Falling, ADS-5102 NICE Does Not Favor Adding Mayzent to NHS England for Active SPMS Currently, the only disease-modifying therapy approved for use in the National Health Service is Betaferon (interferon beta-1b). That’s a 20-year-old treatment considered to be one of the least effective of the DMTs. NICE concedes that clinical trials…
March 22, 2019 News by Jose Marques Lopes, PhD Phase 3 Trial of ADS-5102 Recruiting Participants of All MS Types A Phase 3 trial testing ADS-5102 (amantadine) extended release capsules in all types of multiple sclerosis (MS) is enrolling participants to determine whether the oral therapy can improve walking speed. A total of 570 adults with MS, ages 18 to 70 years, who have difficulty walking will be…
February 21, 2017 News by Patricia Silva, PhD #ACTRIMS2017 – Phase 2 Trial Data Shows Better Walking Speeds in MS Patients Using ADS-5102 Results from aĀ Phase 2 proof-of-concept studyĀ ofĀ ADS-5102Ā (amantadineĀ HCl), showing that multiple sclerosis patients givenĀ the extended-release oral treatment improved their walking speed, will be presentedĀ at ACTRIMS 2017Ā this week. Findings in theĀ poster, āA Phase 2 Study of ADS-5102 (amantadine hydrochloride) Extended Release Capsules in Multiple Sclerosis Patients with Walking Impairment,ā…
November 11, 2016 News by Joana Fernandes, PhD Ampyra/Fampyra for MS Patients ‘Not Recommended’ by NHS Scotland Despite recent studies showing that treatment with Ampyra (Fampyra in Europe; fampridine) improves both walking speed and ability, and offers psychological benefits to patients with multiple sclerosis (MS), the Scottish Medicines Consortium (SMC)Ā recently decided to not recommend the drug for use on the National Health Service (NHS) in Scotland.
September 19, 2016 News by Patricia Silva, PhD #ECTRIMS2016 – Antioxidant Lipoic Acid Appears to Slow SPMS Patients’ Neurodegeneration A pilot study exploring the antioxidant lipoic acid in patients with secondary progressive multiple sclerosis (SPMS) demonstrated that treatment for two years reduced the speed of brain tissue loss and improved the patients’ walking speed. The surprising finding was presented during the āNew directions in progressive MS researchā…